Answers are grounded in this paper and cite their sources.
Abstract Purpose: The study evaluated safety and efficacy of olaratumab+pembrolizumab in patients with unresectable locally advanced/metastatic soft-tissue sarcoma with disease progression on standard treatment. Patients and Methods: This was open-label, multicenter, nonrandomized, phase 1a/1b dose-escalation study followed by cohort expansion (olaratumab+pembrolizumab intravenous infusion). Primary objectives were safety and tolerability. Results: Majority of patients enrolled (41) were female (phase 1a: 9 of 13, phase 1b/dose-expansion cohort [DEC]: 17 of 28), aged <65 years. In phases 1a and 1b, 13 and 26 patients received prior systemic therapy, respectively. Patients received olaratumab 15mg/kg (phase 1a; cohort 1) or 20mg/kg (phase 1a; cohort 2 and phase 1b) and pembrolizumab 200mg (phase 1a/1b). The median (Q1–Q3) duration of therapy (olaratumab) was 6.0 (3.0-11.9) (cohort 1), 14.4 (12.4-20.9) (cohort 2), and 14.0 (6.0-21.8) weeks (DEC). No dose-limiting toxicities and few Grade ≥3 treatment-emergent adverse events (TEAEs, 15 mg/kg: 2 [increased lipase], 20mg/kg: 1 [increased lipase], 1 [colitis], 2 [diarrhea], 3 [anemia]) were reported. Two TEAEs (increased lipase) were related to study discontinuations. Twenty-one patients reported mild (Grade ≤2) TEAE. Phase 1a, disease control rate (DCR):14.3% (1/7, cohort 1); 66.7% (4/6, cohort 2); no responses were reported. Phase 1b, DCR: 53.6% (15/28); objective response rate: 21.4% (6/28) (RECIST and irRECIST criteria). No response in patients with programmed death ligand-1 positive tumors. Conclusions: Antitumor activity was observed in some patients in DEC, combination was well tolerated with manageable safety profile. Further studies are warranted to evaluate efficacy/mechanistic impact of platelet-derived growth factor receptors inhibitor with immune checkpoint modulator coadministration.
No takes yet. Share an insight, caveat, or question.
Schöffski et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: